In 2025, it is possible — and increasingly common — to treat cancer but lose a patient to a drug-resistant infection. This disturbing reality underscores the urgent, and often overlooked intersection of antimicrobial resistance (AMR) [...]
More news
6th September 2023 - INCATE (the INCubator for Antibacterial Therapies in Europe) has successfully reached [...]
INCATE PRESS RELEASE 08, May 2023 For immediate release INCATE has selected Invitris as the [...]
All photographs - Copyright - eventfotografen.com/bamconn GmbH The AMR-Conference, Europe’s leading conference on the antibiotic [...]
The INCATE Selection Committee selected another 5 ventures for Stage I support in Q4 2022. [...]
The INCATE team is expanding and we have three positions open to join the INCATE [...]
Who invests in Antibiotics? What are they looking for? How do they help grow companies? [...]
We are excited to announce our comment highlighting the INCATE mission is now available in [...]
Six new ventures have been selected to join the INCATE portfolio. The six ventures reflect [...]
